Cascade-targeted delivery platform enhances antigen cross-presentation and STING activation for durable cellular
Yuan Xue1,2, Shuting Bai1,3, Yating Wang1
1Key Laboratory of Drug Targeting and Drug Delivery Systems of Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
This study developed a novel nano-emulsion vaccine carrier that enhances cellular immunity by improving antigen presentation and immune activation. The engineered nano-emulsion demonstrates potent antitumor effects, offering a promising strategy for next-generation vaccines.
Area of Science:
- Biotechnology
- Immunology
- Materials Science
Background:
- Subunit vaccines face challenges in eliciting robust cellular immunity due to poor antigen cross-presentation and immune activation.
- Developing effective delivery systems is crucial for overcoming these limitations and enhancing vaccine efficacy.
Purpose of the Study:
- To engineer a novel nano-emulsion platform for improved subunit vaccine delivery.
- To investigate the potential of a palmitic acid-modified human serum albumin (HSA) nano-emulsion as a vaccine carrier.
- To evaluate the nano-emulsion's capacity to enhance antigen cross-presentation, immune activation, and cellular immunity.
Main Methods:
- Engineered nano-emulsions by conjugating human serum albumin (HSA) with fatty acids of varying chain lengths.
- Screened various formulations to identify the most effective carrier, focusing on palmitic acid modification.
- Co-delivered a model antigen (ovalbumin) and a stimulator of interferon genes (STING) agonist using the nano-emulsion.
- Assessed antigen cross-presentation, immune cell activation (CD8+ T cells), memory formation, and antitumor efficacy in murine models.
Main Results:
- Identified a palmitic acid-modified HSA nano-emulsion as a highly effective carrier with self-adjuvant properties.
- Demonstrated cascade-targeted delivery of the nano-emulsion to lymph nodes, antigen-presenting cells (APCs), and the endoplasmic reticulum (ER).
- Showcased synergistic enhancement of antigen cross-presentation and STING pathway activation, leading to significant CD8+ T cell responses and durable memory.
- Achieved potent antitumor efficacy in murine models using the developed nano-emulsion platform.
Conclusions:
- The engineered nano-emulsion platform effectively overcomes key barriers in subunit vaccine delivery.
- This versatile and safe platform shows significant promise for next-generation vaccine design, particularly for enhancing cellular immunity and antitumor responses.
More Related Videos
08:10Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector
Published on: November 28, 2018
07:18HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL
Published on: April 11, 2011
Related Concept Videos
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Cells of the Adaptive Immune Response
Vaccinations
Tumor Immunotherapy
Special Features of Adaptive Immunity
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
